Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2
Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2
Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023
Read more at globenewswire.com